Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp (NGENF) is a clinical-stage biotechnology company advancing novel therapies for nervous system repair. This page provides investors and medical professionals with timely updates on clinical trials, regulatory milestones, and strategic developments.
Access comprehensive coverage of NervGen's progress including NVG-291 Phase 1b/2a trial updates, preclinical research for NVG-300, financial disclosures, and partnership announcements. Our curated news collection enables efficient tracking of both scientific advancements and corporate initiatives in neurorestoration.
Key updates focus on spinal cord injury treatment developments, biomarker validation studies, and operational strategies addressing clinical trial recruitment challenges. Content spans press releases, peer-reviewed findings, and market-sensitive announcements while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to NervGen's evolving story in neurorestorative therapeutics. Check regularly for authoritative reporting on trial outcomes, pipeline expansions, and strategic positioning within the competitive biotech landscape.
NervGen Pharma (OTCQB: NGENF) announced it will present topline results from the chronic cohort of its Phase 1b/2a study of NVG-291 at the 52nd American Spinal Injury Association Annual Scientific Meeting in June 2025. The presentation will cover data from their initial proof-of-concept, double-blind, placebo-controlled clinical trial in spinal cord injury (SCI). The study incorporated both clinical and electrophysiological assessments to maximize the probability of observing efficacy signals. Dr. Daniel Mikol, NervGen's Chief Medical Officer, will present the findings on June 3, 2025, during the Clinical Trial Updates session in Scottsdale, Arizona.
NervGen Pharma (OTCQB: NGENF), a clinical-stage biotech company focused on neuroreparative therapeutics, has announced the granting of 600,000 incentive stock options. The options are structured as follows:
- 500,000 options granted to Directors, exercisable at $4.00 per share for 5 years, vesting quarterly over 1 year
- 100,000 options granted to employees, exercisable at $4.00 per share for 10 years, vesting semi-annually over 4 years
All options comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
The company's President & CEO, Mike Kelly, will deliver a presentation on Monday, May 5, 2025, at 10:00 a.m. EDT. The management team will be available for one-on-one meetings with investors during the conference.
A webcast of the presentation will be accessible online and subsequently archived on NervGen's website for future viewing.
NervGen Pharma (OTCQB: NGENF) has provided an update on its at-the-market (ATM) equity program for Q1 2025. During the quarter ending March 31, 2025, the company, through its agent Stifel Nicolaus Canada, issued and sold 564,500 common shares at a weighted average price of $2.91 per share.
The ATM Program, which was launched on December 19, 2024, generated aggregate gross proceeds of $1,639,761. After paying cash placement fees of $32,796 to the agent, the company secured net proceeds of $1,606,965.
NervGen Pharma (NGENF) has reported its 2024 year-end financial results and key developments. The company completed enrollment in the chronic cohort of its Phase 1b/2a clinical trial for NVG-291 in spinal cord injury (SCI), with topline data expected in early June 2025. The company also initiated enrollment in the subacute cohort and received FDA approval for an expanded access protocol.
Financial highlights include a cash position of $17.3 million as of December 31, 2024, bolstered by a $23 million bought deal financing. R&D expenses increased to $15.7 million from $8.0 million in 2023, while G&A expenses decreased to $9.2 million from $9.7 million. The company reported a net loss of $24.0 million ($0.36 per share) for 2024.
The company's pipeline candidate NVG-300 showed promising preclinical results in ischemic stroke and SCI models, demonstrating decreased lesion volume and improved functional outcomes.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF) has initiated an expanded access policy for its investigational drug NVG-291 following FDA clearance. The policy will allow specific individuals with spinal cord injury (SCI) who have participated in NervGen's clinical trials to continue accessing the treatment.
The company received and processed a physician's request for expanded access for a subject from the chronic cohort of their Phase 1b/2a clinical trial. NVG-291, still in clinical development and not yet approved for market use, has unknown efficacy and potential risks for SCI treatment.
NervGen continues to enroll participants in the subacute cohort of the Phase 1b/2a study, with plans to unblind the efficacy and safety results from the chronic cohort in early June 2025.
NervGen Pharma (OTCQB: NGENF) has announced a virtual investor event scheduled for April 9, 2025, at 10:00 a.m. ET, focusing on their spinal cord injury treatment developments. The event will feature key opinion leaders Dr. Monica Perez from Shirley Ryan AbilityLab and Dr. Steven Kirshblum from Rutgers New Jersey Medical School.
The presentation will cover:
- Current treatment landscape for spinal cord injury patients
- Overview of NervGen's Phase 1b/2a proof-of-concept clinical trial
- Discussion of study endpoints, including electrophysiology
- Review of preclinical data for NVG-291-R
- Phase 1 safety trial results for NVG-291, their first-in-class therapeutic peptide
Clinical data from the Phase 1b/2a trial is expected in the second quarter. The event will conclude with a live Q&A session.
FAQ
What is the current stock price of Nervgen Pharma (NGENF)?
What is the market cap of Nervgen Pharma (NGENF)?
